Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ia/Ib, double-blind, randomized, placebo-controlled, sequential-group study of single ascending doses of KPL-716 in healthy volunteers and subjects with moderate-to-severe atopic dermatitis experiencing moderate-to-severe pruritus following intravenous or subcutaneous administration

Next Previous
Trial Profile

A Phase Ia/Ib, double-blind, randomized, placebo-controlled, sequential-group study of single ascending doses of KPL-716 in healthy volunteers and subjects with moderate-to-severe atopic dermatitis experiencing moderate-to-severe pruritus following intravenous or subcutaneous administration

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vixarelimab (Primary) ; Vixarelimab (Primary)
  • Indications Atopic dermatitis; Pruritus
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 01 Nov 2018 According to a Kiniksa Pharmaceuticals media release, repeated-single-dose Phase 1b results expected in 2H 2019.
    • 15 Sep 2018 According to a Kiniksa Pharmaceuticals media release, data presented at the 27th European Academy of Dermatology and Venereology (EADV) Congress.
    • 15 Sep 2018 Results published in the Kiniksa Pharmaceuticals Media Release
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top